Clinical Trial

Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma

Study acronym: MCC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-08-09; most recent amendment 2026-02-17.
Status change: Not Yet Recruiting → Recruiting 2023-02-14
Trial Details
NCT Number NCT05496036
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Merck Sharp & Dohme LLC
Conditions Merkel Cell Carcinoma
Enrollment 15 participants
Start Date 2023-02-13
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-18